Sedana Medical Research Grant
One of the missions for Sedana Medical is to improve patient outcome through medical innovation. Sedana Medical Research Grant (SMRG) is an integral part of this mission. Via SMRG, Sedana Medical grants 1-3 individual academic researchers between €10 000 and €30 000 per year, for up to two years.
Scope of SMRG 2020/2021
The grant for 2020/2021 will put priority to research targeting effects of volatile anaesthetics in mechanically ventilated patients. However, well-formulated applications for other sedation-related research may also receive funding. Applications that do not follow the instructions or are submitted after the deadline will not be assessed.
Application review process
All applications will be assessed by a committee consisting of Sedana Medical Chief Medical Officer and two independent scientific reviewers. All project information besides the abstract, the applicant information and photo will remain confidential.
Granted applications will be presented on Sedana Medical´s homepage in September 2020. Please send you’re application with the research project headings below to SMRG@sedanamedical.com no later than 30th June 2020.
Click here to download SMRG 2020 – Call for proposals & Instructions for more information.
Sedana Medical Research Foundation 2019 – Awarded projects:
In spring 2019, Sedana Medical Research Foundation had its first call for proposals. Many well-written and interesting applications were submitted. After independent scientific review by two external reviewers and prioritization by Sedana Medical´s Clinical Development Committee, three research projects were prioritized for funding in 2019.
Title: Feasibility and safety of inhaled sedation in ECMO patients undergoing ultra-protective low frequency ventilation.
Investigators: Dr Giuseppe Foti, Associate professor and Director and dr Marco Giani, Department of Anesthesia and Intensive Care Department of Monza University Hospital, Italy.
This study will investigate inhaled sedation delivered with the AnaConDa in Acute Respiratory Distress Syndrome (ARDS) patients undergoing veno-venous extracorporeal membrane oxygenation with ultra-protective tidal volumes and low-frequency ventilation. Patients on Extracorporeal membrane oxygenation (ECMO) will receive intravenous sedation and inhaled sedation with sevoflurane in randomized order. Sedation feasibility and sedation offset will be compared between sedation strategies. While retrospective data are promising, a prospective study would confirm that inhaled anaesthetics, that appear to be lung-protective, may be used in patients normally considered too sick for uptake and elimination via the lungs.
Title: : Inhaled anaesthetic effects on Mean Pulmonary Arterial Pressure in ARDS patients.
Investigators: Dr Gabriel Parzy, Dr Jean-Marie Forel, and Dr Laurent Papazian, Professor, Medical Intensive Care Unit service, Intensive Care Unit, Hôpital Nord, Marseille, France.
The main objective in this research project is to investigate potential reduction of mean pulmonary arterial pressure (mPAP) during inhaled sedation via the AnaConDa, in moderate or severe ARDS patients. ARDS is associated with cardiopulmonary complications, including cor pulmonale and carries a high mortality. While inhaled anaesthetics are known to be vasodilatory in general, potential such effects in ARDS are not well studied previously. Mechanically ventilated ARDS patients will receive sevoflurane and mPAP will be measured before and one hour after the introduction of low-dose sevoflurane. Reduction of pulmonary pressures with inhaled anaesthetics may potentially improve outcomes in ARDS patients.
Title: Inhaled Sevoflurane for Immunomodulation in Patients with Septic Shock – a pilot study.
Investigators: Dr Martin Schläpfer, Privatdozent, and Dr Beatrice Beck-Schimmer, Professor, Vice President Medicine, Institutes of Anesthesiology and Physiology, University and University Hospital Zurich, Switzerland.
This study will shed light on potential anti-inflammatory effects of inhaled anaethetics via the AnaConDa in septic shock. The hypothesis is that inflammatory mediators, important players in the pathophysiology of septic shock and multiple organ failure, will be attenuated with the intervention. Patients with septic shock will be randomized to receive either sevoflurane 0.5-1.5% or standard sedation for a four-hour period and the primary endpoint is levels of interleukin 6 (IL-6) over the first 120 hours. If IL-6 is reduced by this therapy, its use may improve patient outcomes, such as mortality, in a critically ill patient group.
The Sedana Medical Team are happy for the great interest in moving research forward and wish to improve the care of patients in this important medical field. We wish all research groups success in their research and look forward to the results of the projects. The next SMRF Call for proposals is planned for spring 2020.